MIMEDX develops and commercializes tissue-based healing solutions for wound care, burn, and surgical applications, primarily serving the advanced wound care market for chronic wounds that fail conventional treatment and surgical recovery settings. The company manufactures placental allografts using its proprietary PURION process, supplemented by partnerships for complementary products including xenografts and other regenerative matrices, and has built competitive differentiation through extensive clinical evidence, established reimbursement relationships with Medicare and private payers, and a direct sales force across physician offices, hospitals, and wound centers. Revenue is driven by third-party reimbursement, with domestic sales dominating and international expansion in Japan, while the company faces ongoing competition from larger diversified medical device firms and numerous entrants to the tissue substitute market.